Advancing Nuclear Medicine
FIELD-LAB
- Supports medical product development
- Unique nuclear infrastructure
- Supply of promising medical isotopes
Are you stuck in the process of developing a new nuclear medicine? We may be the right partner to help you out.
Phases
Preclinical TRL 1-5
Laboratory and animal testing to answer safety questions.Clinical TRL 6
Tests on safety and dosage.Clinical TRL 7
Phase II: Tests on efficacy and side effects. Phase III: Confirming research: testing of final dosage on usability and effectiveness.Registration & Upscaling
Phase III (Registration & upscaling): Registration and market launch of new nuclear drug.About FIELD-LAB
FIELD-LAB is a drug discovery facility that will help you to speed up the development and market launch of new nuclear drugs for cancer treatment. Through supply of small batches of radio chemicals and radio pharmaceuticals, we meet the need of Bio Pharma scientists and start-up ventures for research materials. This will drive both their ambitions to develop a new drug.
Nuclear infrastructure
FIELD-LAB is part of a unique and complete nuclear infrastructure.
- High flux reactor
- Radiological laboratories
- Hot cell laboratories
- GMP small scale production facility
Read more about Nuclear Infrastructure
Research
Currently, research is done on the production and development of various isotopes:
- Pb-212
- Pt-195m CISSPECT
- Lu-177 n.c.a
Read more
- High in demand medical isotope
- Bèta-radiator
- Independent supply by FIELD-LAB
- High Quality
- Chemotherapeutic drug (cisplatin) integrated with Pt-195m by synthesis
- Chemotherapeutic function remains the same
- Single alpha emitting during decay
- Ideal halflife (~10 hour)
- Reliable supply
Get to know FIELD-LAB
Learn more about FIELD-LAB and its importance. Discover our global network for pre-clinical and clinical research: research that is part of the development of every new medical product.
- Supply of radiochemical solutions and radiopharmaceuticals to laboratories
- Both research and GMP grade
- Creation of radiochemical processes using innovative isotopes
- Collaboration between academic and industrial partners
- Portal to a fast-growing network with an open innovation culture
Our partners
FIELD-LAB is created for and together with partners from different backgrounds. Some of the finest Dutch and British UMC’s have committed themselves to be part of this initiative. They believe in the beneficial results that will be brought to the Nuclear Medicine society. In addition, the partnerships that arise from FIELD-LAB form a portal to a fast growing network, which results in an open innovation environment.
Partners we work with
FIELD-LAB articles
Already in 2001, NRG supported the development of Peptide Receptor Radionuclide Therapy with carrier added Lutetium-177 (Lu-177 c.a.) by the supply of Lutetium-177 trichloride as a radiochemical. Nowadays, Lu-177 no carrier added is preferably used. “Lu-177 n.c.a. has a higher specific activity and thus radiolabeling efficiency, than lu-177 c.a.”, according to Marion Chomet, lead scientist at FIELD-LAB. Chomet and her colleagues are now fine-tuning and finalizing their custom made lutetium-177 n.c.a. process. But there are several challenges and practical considerations that they are facing.
The major bottleneck for research and development of radiopharmaceuticals for targeted alpha therapy is its limited availability. The irradiation of radium-226 could be a game changer as the amounts produced using this method could fulfill the market needs for alpha-emitters. However, there are several challenges in 226Ra target preparation and further processing of irradiated targets.
Karlijn van der Schilden
Get in touch
Karlijn van der Schilden
R&D Manager Medical Isotopes
T. +31 224 56 8018
M. k.vanderschilden@nrg.eu
Vinod Ramnandanlal
Get in touch
Vinod Ramnandanlal
Commercial Director
T. +31 224 56 4196
M. ramnandanlal@nrg.eu